Eli Lilly is rolling out a multibillion-dollar welcome mat for psychedelics, agreeing to buy AtaiBeckley in a deal that puts roughly $2.8 billion in cash on the table up front, with more tied to performance. The Indianapolis drugmaker is snapping up a late‑stage psychedelic developer as big pharma firms race to lock in rapid-acting mental health treatments.
Deal terms and the immediate payment
According to CNBC, Lilly will pay $6.75 per AtaiBeckley share in cash and could pay up to an additional $2.50 per share tied to development and commercial milestones. That works out to about $2.8 billion up front and roughly $1 billion in contingent payments. CNBC also reports that the offer represents a notable premium to recent trading and sent AtaiBeckley stock sharply higher in premarket action.
The drug at the center: BPL‑003
AtaiBeckley’s lead candidate, BPL‑003, is an intranasal formulation of mebufotenin (a 5‑MeO‑DMT analogue) that has earned Breakthrough Therapy designation after encouraging mid‑stage results. The company has described the treatment as a short, clinic‑administered dosing experience, with patients monitored for roughly two hours after dosing. It has told investors that the Phase‑3 ReConnection program is on track, with topline readouts aimed for early 2029. AtaiBeckley and its Q1 update lay out the trial timing and the prior safety and efficacy readouts.
Why Lilly is buying in
Industry analysts say the acquisition lines up with Lilly’s recent strategy of buying later‑stage, relatively de‑risked assets to thicken its neuroscience and psychiatry pipeline alongside its blockbuster metabolic franchises. Reuters and other outlets have flagged growing interest from major drugmakers in psychedelic medicines, which promise fast onset and potentially durable effects for treatment‑resistant depression and other conditions.
Market reaction and what’s next
Shares of AtaiBeckley jumped on the news, reflecting investor appetite for an exit that assigns a rich value to near‑term Phase‑3 assets, per CNBC. The companies are expected to follow with regulatory and SEC filings that spell out the full purchase agreement and timing. Shareholders, rivals and anyone watching the psychedelics space will be gauging whether this deal speeds up the next wave of big pharma moves in the category.
